The CRUSE® app has been developed for the self-management of chronic spontaneous urticaria (CSU), and to help physicians develop personalised treatment strategies for patients. touchIMMUNOLOGY were delighted to speak with Prof. Marcus Maurer (Professor of Dermatology and Allergy, Charité – Universitätsmedizin Berlin) about the availability, functions, and clinical implications of the app.
Questions:
- Please could you give a brief overview of the CRUSE® app, where the app is available and its functions?
- How will the app support patients in the self-management of chronic spontaneous urticaria?
- How will the CRUSE® app help physicians to develop personalised treatment strategies for patients?
Disclosures: Marcus Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Alvotech, Amgen, Aquestive, Aralez, AstraZeneca, Astria, Bayer, BioCryst, Blueprint, Celldex, Celltrion, Centogene, CSL Behring, Evoemmune, GSK, Ipsen, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnoloy, Pharvaris, Resonance Medicine, Sanofi/Regeneron, Septerna, Takeda, Teva, Trial Form Support International AB, Third HarmonicBio, Valenza Bio, Yuhan Corporation, Zurabio.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Click here for more content on urticaria.
Transcript
Please could you give a brief overview of the CRUSE* app, where the app is available and its functions? (00:22)
CRUSE, and that is spelled C-R-U-S-E, is the chronic urticaria self-evaluation app developed by UCARE, the Urticaria Centers of Reference and Excellence, and made available first about a year ago. It is now in 14 countries, in their national language, with the national medication list, so that people can document their disease activity, their disease control, their angioedema, their impairment, And it’s also available globally in an English and a Ukrainian version, and the Ukrainian version is very interesting because you can enter anywhere in Ukrainian, very helpful for refugees, and the outcome, the results are reported in the language of the physician in the country where you are. So Ukraine, that’s what the project is called, really helps patients who otherwise may have a language barrier problem.
How will the app support patients in the self-management of chronic spontaneous urticaria? (01:32)
Self-management of chronic spontaneous urticaria is essential for patients. They have their signs and symptoms every day. They need help and guidance on how to achieve control. That’s the medication on the one hand, but it’s also tools that allow them to see the progress they make. Where do they stand? Do they achieve the aim of treatment, complete response? How far off are they? That’s what we, as treating physicians need, in order to optimize the treatment, individualize the treatment, and therefore, thereby, help every patient to achieve the goals of our treatment.
How will the CRUSE* app help physicians to develop personalised treatment strategies for patients? (02:16)
Well, as of now, we have worked mostly with open questions to our patients, “How are you?”, “Has the new treatment helped you?”. Sometimes, we use patient reported outcome measures like the Urticaria Control Test or the Urticaria Activity Score or the Angioedema Activity Score, but we need to improve that and work with PROMs in every patient. And the CRUSE app obviously makes it very easy for patients to provide that information. There are daily reminders, it’s a very easy to use interface and an immediate option to share results with the treating physicians. My patients do that before they come and see me so that I know where they stand, and I can therefore provide individual treatment and guidance based on the information that patients have shared with me.
Subtitles and transcript are autogenerated
